Amgen ' s Investigational Targeted Treatment Bemarituzumab Granted Breakthrough Therapy Designation

THOUSAND OAKS, Calif., April 19, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for investigational bemarituzumab as...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials